Home » Stocks » GH

Guardant Health, Inc. (GH)

Stock Price: $110.80 USD -3.13 (-2.75%)
Updated May 13, 2021 2:46 PM EDT - Market open
Market Cap 12.15B
Revenue (ttm) 297.89M
Net Income (ttm) -335.71M
Shares Out 101.12M
EPS (ttm) -3.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $110.80
Previous Close $113.93
Change ($) -3.13
Change (%) -2.75%
Day's Open 117.27
Day's Range 108.03 - 117.64
Day's Volume 812,220
52-Week Range 74.31 - 181.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 1 0 0 2 Indifferent 0 ...

6 days ago - Benzinga

CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.

Other stocks mentioned: CDNA, EXAS
6 days ago - The Motley Fool

Guardant Health (GH) delivered earnings and revenue surprises of 40.24% and 5.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vas...

6 days ago - Business Wire

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announces the appointment of Craig Eagle, MD as the company's new Chief Medical Officer (...

1 week ago - Business Wire

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2021 He...

2 weeks ago - Business Wire

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Daiichi Sankyo, Inc. (Daiichi Sankyo) to pursue regulatory approval and commercia...

2 weeks ago - Business Wire

Their liquid biopsies are giving doctors new and better tools to spot, track, and treat cancers.

Other stocks mentioned: RHHBY
2 weeks ago - The Motley Fool

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2021 after market ...

1 month ago - Business Wire

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, ...

1 month ago - Business Wire

Bear of the Day: Guardant Health (GH)

1 month ago - Zacks Investment Research

The company's newest product received a key approval in New York.

1 month ago - The Motley Fool

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) announced that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the Guardant R...

1 month ago - Business Wire

Which healthcare company is a better play for the next decade?

Other stocks mentioned: ABMD
1 month ago - The Motley Fool

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) announced that the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status...

1 month ago - Business Wire

HTHT, FNLPF, GMRE, THRY, and GH have been added to the Zacks Rank #5 (Strong Sell) List on March 29, 2021

Other stocks mentioned: FNLPF, GMRE, HTHT, THRY
1 month ago - Zacks Investment Research

This liquid biopsy pioneer is going after a huge potential market.

1 month ago - The Motley Fool

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is joining forces with leading patient advocacy groups to expand the Clear Your View init...

1 month ago - Business Wire

Innovation is risky, and these companies are all in.

Other stocks mentioned: FLDM, NNOX
1 month ago - The Motley Fool

The diagnostic testing company's growth may be slowing, but this shareholder isn't worried.

2 months ago - The Motley Fool

The overall stock market sell-off pulled Guardant Health's shares down.

2 months ago - The Motley Fool

This under-the-radar diagnostics company is thriving yet reasonably priced.

Other stocks mentioned: CDNA
2 months ago - The Motley Fool

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients wi...

2 months ago - Business Wire

The company reported disappointing Q4 results.

2 months ago - The Motley Fool

The company beat revenue expectations, but its bottom-line performance and 2021 outlook weren't what investors hoped for.

2 months ago - The Motley Fool

Shares of Guardant Health (NASDAQ:GH) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 248.15% over the past year to ($0.94), which miss...

2 months ago - Benzinga

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vas...

2 months ago - Business Wire

On Wednesday, February 24, Guardant Health (NASDAQ:GH) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

2 months ago - Benzinga

These two companies have exciting long-term prospects.

Other stocks mentioned: EXAS
2 months ago - The Motley Fool

This cannabis producer and liquid biopsy pioneer should make investors a lot of money.

Other stocks mentioned: CRLBF
2 months ago - The Motley Fool

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following virtual investor confe...

2 months ago - Business Wire

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the availability of Guardant Reveal™, the first blood-only liquid biopsy test f...

2 months ago - Business Wire

Here's why they're such great picks.

Other stocks mentioned: FVRR, ISRG
3 months ago - The Motley Fool

If you screen the market for stocks that have a current ratio higher than 2 and more working capital than long-term debt, as Benjamin Graham, the pioneer of value investing, recommended, the chances tha...

Other stocks mentioned: ASND, TPTX
3 months ago - GuruFocus

Each of them has clear potential catalysts ahead.

Other stocks mentioned: CRLBF, SQ
3 months ago - The Motley Fool

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 202...

3 months ago - Business Wire

Don't get caught chasing the hype.

Other stocks mentioned: AAPL, VRTX
3 months ago - The Motley Fool

Patience is a virtue that should prove valuable with these stocks.

Other stocks mentioned: ETSY, SQ
3 months ago - The Motley Fool

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH). Despite guideline recommendations for comprehensive genomic profiling (CGP) of all patients with advanced non-small cell lung c...

3 months ago - Business Wire

It's a big bet but not a big gamble.

Other stocks mentioned: EDIT, ISRG, TDOC, VRTX, XBI
3 months ago - The Motley Fool

Here's how they'll do it.

Other stocks mentioned: FVRR, TTD
3 months ago - The Motley Fool

BARCELONA, Spain & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d'Hebron Institute of Oncology (VHIO), one of Europe's leadin...

3 months ago - Business Wire

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of G...

3 months ago - Business Wire

And they could do it sooner rather than later.

Other stocks mentioned: CRLBF, FVRR
3 months ago - The Motley Fool

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan...

4 months ago - Business Wire

As is the case every year, the major Wall Street firms we cover here at 24/7 Wall St.

Other stocks mentioned: AVTR, HCA, HOLX, CTLT
4 months ago - 24/7 Wall Street

All three could be huge winners in the new year -- and over the long run.

Other stocks mentioned: ISRG, VRTX
4 months ago - The Motley Fool

All three have already made investors a lot of money this year.

Other stocks mentioned: MDB, TRUP
4 months ago - The Motley Fool

About GH

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the e... [Read more...]

Industry
Diagnostics & Research
IPO Date
Oct 4, 2018
Stock Exchange
NASDAQ
Ticker Symbol
GH
Full Company Profile

Financial Performance

In 2020, GH's revenue was $286.73 million, an increase of 33.75% compared to the previous year's $214.38 million. Losses were -$253.78 million, 235.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price forecast is 178.30, which is an increase of 60.92% from the latest price.

Price Target
$178.30
(60.92% upside)
Analyst Consensus: Strong Buy